Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

Abstract

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

What is claimed is:  
     
         1 . A compound of Formula I: 
       A−D−B   (I) 
       or a pharmaceutically acceptable salt thereof, wherein 
 D is —NH—C(O)—NH—,  
 A is a substituted moiety of up to 40 carbon atoms of the formula: —L—(M−L 1 ) q , where L is a 5 or 6 membered cyclic structure bound directly to D, L 1  comprises a substituted cyclic moiety having at least 5 members, M is a bridging group having at least one atom, q is an integer of from 1-3; and each cyclic structure of L and L 1  contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur, and  
 B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur,  
 wherein L 1  is substituted by at least one substituent selected from the group consisting of —SO 2 R x , —C(O)R x  and —C(NR y ) R z ,  
 Ry is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo,  
 R Z  is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;  
 R X  is R Z  or NR a R b  where R a  and R b  are 
 a) independently hydrogen,  
 
 a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or  
 —OSi(R f ) 3  where R f  is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or 
 b) R a  and R b  together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or  
 c) one of R a  or R b  is —C(O)—, a C 1 -C 5  divalent alkylene group or a substituted C 1 -C 5  divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C 1 -C 5  divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;  
 
 where B is substituted, L is substituted or L 1  is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and Wn, where n is 0-3;  
 wherein each W is independently selected from the group consisting of —CN, —CO 2 R 7 , —C(O)NR 7 R 7 , —C(O)—R 7 , —NO 2 , —OR 7 , —SR 7 , —NR 7 R 7 , —NR 7 C(O)OR 7 , —NR 7 C(O)R 7 , —Q—Ar, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of —CN, —CO 2 R 7 , —C(O)R 7 , —C(O)NR 7 R 7 , —OR 7 , —SR 7 , —NR 7 R 7 , —NO 2 , —NR 7 C(O)R 7 , —NR 7 C(O)OR 7  and halogen up to per-halo; with each R 7  independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen,  
 wherein Q is —O—, —S—, —N(R 7 )—, —(CH 2 ) m —, —C(O)—, —CH(OH)—, —(CH 2 ) m O—, —(CH 2 ) m S—, —(CH 2 ) m N(R 7 )—, —O(CH 2 ) m — CHX a —, CX a   2 —, —S—(CH 2 ) m — and —N(R 7 )(CH 2 ) m —, where m=1-3, and X a  is halogen; and  
 Ar is a 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by Z n1 , wherein n1 is 0 to 3 and each Z is independently selected from the group consisting of —CN, —CO 2 R 7 , —C(O)R 7 , —C(O)NR 7 R 7 , —NO 2 , —OR 7 , —SR 7  —NR 7 R 7 , —NR 7 C(O)OR 7 , -NR 7 C(O)R 7 , and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents selected from the group consisting of —CN, —CO 2 R 7 , —COR 7 , —C(O)NR 7 R 7 , —OR 7 , —SR 7 , —NO 2 , —NR 7 R 7 , —NR 7 C(O)R 7 , and —NR 7 C(O)OR 7 , with R 7  as defined above.  
 
     
     
         2 . A compound as in    claim 1    wherein: 
 R y  is hydrogen, C 1-10  alkyl, C 1-10  alkoxy, C 3-10  cycloalkyl having 0-3 heteroatoms, C 2-10  alkenyl, C 1-10  alkenoyl, C 6-12  aryl, C 3-12  hetaryl having 1-3 heteroatoms selected from N, S and , C 7-24  aralkyl, C 7-24  alkaryl, substituted C 1-10  alkyl, substituted C- 1-10  alkoxy, substituted C 3-10  cycloalkyl having 0-3 heteroatoms selected from N, S and O, substituted C 6  -C 14  aryl, substituted C 3-12  hetaryl having 1-3 heteroatoms selected from N, S and O, substituted C 7-24  alkaryl or substituted C 7 -C 24  aralkyl, where R y  is a substituted group, it is substituted by halogen up to per halo,  
 R Z  is hydrogen, C 1-10  alkyl, C 1-10  alkoxy, C 3-10  cycloalkyl having 0-3 heteroatom, C 2-10  alkenyl, C 1-10  alkenoyl, C 6-12  aryl, C 3 -C 12  hetaryl having 1-3 heteroatoms selected from, S, N and  0 , C 7-24  alkaryl, C 7-24  aralkyl, substituted C 1-10  alkyl, substituted C 1-10  alkoxy, substituted C 6 -C 14  aryl, substituted C 3 -C 10  cycloalkyl having 0-3 heteroatoms selected from S, N and O, substituted C 3-12  hetaryl having 1-3 heteroatoms selected from S, N and O, substituted C 7-24  alkaryl or substituted C 7 -C 24  aralkyl where R Z  is a substituted group, it is substituted by halogen up to per halo, hydroxy, C 1-10  alkyl, C 3-12  cycloalkyl having 0-3 heteroatoms selected from O, S and N, C 3-12  hetaryl having 1-3 heteroatoms selected from N, S and O, C 1-10  alkoxy, C 6-12  aryl, C 1-6  halo substituted alkyl up to per halo alkyl, C 6 -C 12  halo substituted aryl up to per halo aryl, C 3 -C 12  halo substituted cycloalkyl up to per halo cycloalkyl having 0-3 heteroatoms selected from N, S and O, halo substituted C 3 -C 12  hetaryl up to per halo hetaryl having 1-3 heteroatoms selected from O, N and S, halo substituted C 7 -C 24  aralkyl up to per halo aralkyl, halo substituted C 7 -C 24  alkaryl up to per halo alkaryl, and —C(O)R g ,  
 R a  and R b  are,  
 a) independently hydrogen, 
 a carbon based moiety selected from te group consisting of C 1 -C 10  alkyl, C 1 -C 10  alkoxy, C 3-10  cycloalkyl, C 2-10  alkenyl, C 1-10  alkenoyl, C 6-12  aryl, C 3-12  hetaryl having 1-3 heteroatoms selected from O, N and S, C 3-12  cycloalkyl having 0-3 heteroatoms selected from N, S and O, C 7-24  aralkyl, C 7 -C 24  alkaryl, substituted C 1-10  alkyl, substituted C 1-10  alkoxy, substituted C 3-10  cycloalkyl, having 0-3 heteroatoms selected from N, S and O, substituted C 6-12  aryl, substituted C 3-12  hetaryl having 1-3 heteroatoms selected from N, S and O, substituted C 7-24  aralkyl, substituted C 7-24  alkaryl, where R a  and R b  are a substituted group, they are substituted by halogen up to per halo, hydroxy, C 1-10  alkyl, C 3-12  cycloalkyl having 0-3 heteroatoms selected from O, S and N, C 3-12  hetaryl having 1-3 heteroatoms selected from N, S and O, C 1-10  alkoxy, C 6-12  aryl, C 1-6  halo substituted alkyl up to per halo alkyl, C 6 -C 12  halo substituted aryl up to per halo aryl, C 3 -C 12  halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C 3 -C 12  hetaryl up to per halo heteraryl, halo substituted C 7 -C 24  aralkyl up to per halo aralkyl, halo substituted C 7 -C 24  alkaryl up to per halo alkaryl, and —C(O)R g ; or  
 —OSi(R f ) 3  where R f  is hydrogen, C 1-10  alkyl, C 1-10  alkoxy, C 3 -C 10  cycloalkyl having 0-3 heteroatoms selected from O, S and N, C 6-12  aryl, C 3 -C 12  hetaryl having 1-3 heteroatoms selected from O, S and N, C 7-24  aralkyl, substituted C 1-10  alkyl, substituted C 1 -C 10  alkoxy, substituted C 3 -C 12  cycloalkyl having 0-3 heteroatoms selected from O, S and N, substituted C 3 -C 12  heteraryl having 1-3 heteroatoms selected from O, S, and N, substituted C 6-12  aryl, and substituted C 7-24  alkaryl, where R f  is a substituted group it is substituted halogen up to per halo, hydroxy, C 1-10  alkyl, C 3-12  cycloalkyl having 0-3 heteroatoms selected from O, S and N, C 3-12  hetaryl having 1-3 heteroatoms selected from N, S and O, C 1-10  alkoxy, C 6-12  aryl, C 7 -C 24  alkaryl, C 7 -C 24  aralkyl, C 1-6  halo substituted alkyl up to per halo alkyl, C 6 -C 12  halo substituted aryl up to per halo aryl, C 3 -C 12  halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C 3 -C 12  hetaryl up to per halo heteraryl, halo substituted C 7 -C 24  aralkyl up to per halo aralkyl, halo substituted C 7 -C 24  alkaryl up to per halo alkaryl, and —C(O)R g , or  
 
 b) R a  and R b  together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O with substituents selected from the group consisting of halogen up to per halo, hydroxy, C 1-10  alkyl, C 3-12  cycloalkyl having 0-3 heteroatoms selected from O, S and N, C 3-12  hetaryl having 1-3 heteroatoms selected from N, S and O, C 1-10  alkoxy, C 6-12  aryl, C 7 -C 24  alkaryl, C 7 -C 24  aralkyl, halo substituted C 1-6  alkyl up to per halo alkyl, halo substituted C 6 -C 12  aryl up to per halo aryl, halo substituted C 3 -C 12  cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C 3 -C 12  hetaryl up to per halo heteraryl, halo substituted C 7 -C 24  aralkyl up to per halo aralkyl, halo substituted C 7 -C 24  alkaryl up to per halo alkaryl, and —C(O)R g , or  
 c) one of R a  or R b  is —C(O)—, a C 1 -C 5  divalent alkylene group or a substituted C 1 -C 5  divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members,  
 wherein the substituents of the substituted C 1 -C 5  divalent alkylene group are selected from the group consisting of halogen, hydroxy, C 1-10  alkyl, C 3-12  cycloalkyl having 0-3 heteroatoms selected from O, S and N, C 3-12  hetaryl having 1-3 heteroatoms selected from N, S and O, C 1-10  alkoxy, C 6-12  aryl, C 7 -C 24  alkaryl, C 7 -C 24  aralkyl, C 1-6  halo substituted alkyl up to per halo alkyl, C 6 -C 12  halo substituted aryl up to per halo aryl, C 3 -C 12  halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C 3 -C 12  hetaryl up to per halo heteraryl, halo substituted C 7 -C 24  aralkyl up to per halo aralkyl, halo substituted C 7 -C 24  alkaryl up to per halo alkaryl, and —C(O)R g ,  
 where R g  is C 1-10  alkyl; —CN, —CO 2 R d , —OR d , —SR d , —NO 2 , —C(O) R e , —NR d R e , —NR d  C(O)OR e  and —NR d  C(O)R e , and R d  and R e  are independently selected from the group consisting of hydrogen, C 1-10 , alkyl, C 1-10  alkoxy, C 3-10  cycloalkyl having 0-3 heteroatoms selected from O, N and S, C 6-12  aryl, C 3 -C 12  hetaryl with 1-3 heteroatoms selected from O, N and S and C 7 -C 24  aralkyl, C 7 -C 24  alkaryl, up to per halo substituted C 1 -C 10  alkyl, up to per halo substituted C 3 -C 10  cycloalkyl having 0-3 heteroatoms selected from O, N and S, up to per halo substituted C 6 -C 14  aryl, up to per halo substituted C 3 -C 12  hetaryl having 1-3 heteroatoms selected from O, N, and S, halo substituted C 7 -C 24  alkaryl up to per halo alkaryl, and up to per halo substituted C 7 -C 24  aralkyl,  
 W is independently selected from the group consisting of —CN, —CO 2 R 7 , —C(O)NR 7 R 7 , —C(O)—R 7 , —NO 2 , —OR 7 , —SR 7 , —NR 7 R 7 , —NR 7 C(O)WR 7 , —NR 7 C(O)R 7  C 1 C 10  alkyl, C 1 -C 10  alkoxy, C 2 -C 10  alkenyl, C 1 -C 10  alkenoyl, C 3 -C 10  cycloalkyl having 0-3 heteroatoms selected from O, S and N, C 6 -C 14  aryl, C 7 -C 24  alkaryl, C 7 -C 24  aralkyl, C 3 -C 12  heteroaryl having 1-3 heteroatoms selected from O, N and S, C 4 -C 23  alkheteroaryl having 1-3 heteroatoms selected from O, N and S, substituted C 1 -C 10  alkyl, substituted C 1 -C 10  alkoxy, substituted C 2 -C 10  alkenyl, substituted C 1 -C 10  alkenoyl, substituted C 3 -C 10  cycloalkyl having 0-3 heteroatoms selected from O, N and S, substituted C 6 -C 12  aryl, substituted C 3 -C 12  hetaryl having 1-3 heteroatoms selected from O, N and S, substituted C 7 -C 24  aralkyl, substituted C 7 -C 24  alkaryl, substituted C 4 -C 23  alkheteroaryl having 1-3 heteroatoms selected from O, N and S, and —Q—Ar;  
 R 7  is independently selected from H, C 1 -C 10  alkyl, C 1 -C 10  alkoxy, C 2 -C 10  alkenyl, C 1 -C 10  alkenoyl, C 3 -C 10  cycloalkyl having 0-3 heteroatoms selected from O, S and N, C 6 -C 14  aryl, C 3 -C 13  hetaryl having 1-3 heteroatoms selected from 0, N and S, C 7 -CI 4  alkaryl, C 7  -C 24  aralkyl, C 4 -C 23  alkheteroaryl having 1-3 heteroatoms selected from O, N and S, up to per-halosubstituted C 1 -C 10  alkyl, up to per-halosubstituted C 3 -C 10  cycloalkyl having 0-3 heteroatoms selected from O, N and S, up to per-halosubstituted C 6 -C 14  aryl, up to per-halosubstituted C 3 -C 13  hetaryl having 1-3 heteroatoms selected from O, N and S, up to per-halosubstituted C 7 -C 24  aralkyl, up to per-halosubstituted C 7 -C 24  alkaryl, and up to per-halosubstituted C 4 -C 23  alkheteroaryl; and  
 each Z is independently selected from the group consisting of —CN, —CO 2 R 7 , —C(O)R 7 , —C(O)NR 7 R 7 , —NO 2 , —OR 7 , —SR 7  —NR 7 R 7 , —NR 7 C(O)OR 7 , —NR 7 C(O)R 7 , C 1 -C 10  alkyl, C 1 -C 10  alkoxy, C 2 -C 10  alkenyl, C 1 -C 10  alkenoyl, C 3 -C 10  cycloalkyl having 0-3 heteroatoms selected from O, N and S, C 6 -C 14  aryl, C 3 -C 13  hetaryl having 1-3 heteroatoms selected from O, N and S, C 7 -C 24  alkaryl, C 7 -C 24  aralkyl, C 4 -C 23  alkheteroaryl having 1-3 heteroatoms selected from O, N and S, substituted C 1 -C 10  alkyl, substituted C 1 -C 10  alkoxy, substituted C 2 -C 10  alkenyl, substituted C 1 -C 10  alkenoyl, substituted C 3 -C 10  cycloalkyl having 0-3 heteroatoms selected from O, N and S, substituted C 6 -C 12  aryl, substituted C 7 -C 24  alkaryl, substituted C 7 -C 24  aralkyl and substituted C 4 -C 23  alkheteroaryl having 1-3 heteroatoms selected from O, N and S; wherein if Z is a substituted group, the one or more substituents are selected from the group consisting of —CN, —CO 2 R 7 , —COR 7 , —C(O)NR 7 R 7 , —OR 7 , —SR 7 , —NO 2 , —NR 7 R 7 , —NR 7 C(O)R 7 , and —NR 7 C(O)OR 7 .  
 
     
     
         3 . A compound as in    claim 1    wherein M is one or more bridging groups selected from the group consisting of —O—, —S—, —N(R 7 )—, —(CH 2 ) m —, —C(O)—, —CH(OH)—, —(CH 2 ) m O—, —(CH 2 ) m S—, —(CH 2 ) m N(R 7 )—, —O(CH 2 ) m — CHX a —, —CX a   2 —, —S—(CH 2 ) m — and —N(R 7 )(CH 2 ) m —, where m=1-3, X a  is halogen and R 7 is as defined in    claim 1   .  
     
     
         4 . A compound as in    claim 1    wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by —OH.  
     
     
         5 . A compound as in    claim 1    wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by a moiety having an ionizable hydrogen and a pKa of 10 or less.  
     
     
         6 . A compound of    claim 1    wherein B of Formula I is a substituted or unsubstituted six member aryl moiety or six member hetaryl moiety, said hetaryl moiety having 1 to 4 members selected from the group of hetaryl atoms consisting of nitrogen, oxygen and sulfur with the balance of the hetaryl moiety being carbon.  
     
     
         7 . A compound of    claim 1    wherein B of Formula I is an unsubstituted phenyl group, an unsubstituted pyridyl group, an unsubstituted pyrimidinyl, a phenyl group substituted by a substituent selected from the group consisting of halogen and Wn wherein W and n are as defined in    claim 1   , a pyrimidinyl group substituted by a substituent selected from the group constituting of halogen and Wn, whereas W and n are as defined in    claim 1   , or a substituted pyridyl group substituted by a substituent selected from the group consisting of halogen and Wn wherein W and n are as defined in    claim 1   .  
     
     
         8 . A compound of    claim 6    wherein B of Formula I is a substituted phenyl group, a substituted pyrimidinyl group, or substituted pyrridyl group substituted 1 to 3 times by 1 or more substituents selected from the group consisting of —CN, halogen, C 1 -C 10  alkyl, C 1 -C 10  alkoxy, —OH, up to per halo substituted C 1 -C 10  alkyl, up to per halo substituted C 1 -C 10  alkoxy or phenyl substituted by halogen up to per halo.  
     
     
         9 . A compound of    claim 1   , wherein L, the six member cyclic structure bound directly to D, is a substituted or unsubstituted 6 member aryl moiety or a substituted or unsubstituted 6 member hetaryl moiety, wherein said hetaryl moiety has 1 to 4 members selected from the group of heteroatoms consisting of nitrogen, oxygen and sulfur with the balance of said hetaryl moiety being carbon, wherein the one or more substituents are selected from the group consisting of halogen and Wn wherein W and n are as defined in    claim 1   .  
     
     
         10 . A compound of    claim 8   , wherein L, the 6 member cyclic structure bound directly to D, is a substituted phenyl, unsubstituted phenyl, substituted pyrimidinyl, unsubstituted pyrimidinyl, substituted pyridyl or unsubstituted pyridyl group.  
     
     
         11 . A compound of    claim 1   , wherein said substituted cyclic moiety L 1  comprises a 5 to 6 membered aryl moiety or hetaryl moiety, wherein said heteraryl moiety comprises 1 to 4 members selected from the group of heteroatoms consisting of nitrogen, oxygen and sulfur.  
     
     
         12 . A compound of    claim 1   , wherein said substituted cyclic moiety L 1  is phenyl, pyridinyl or pyrimidinyl.  
     
     
         13 . A compound of    claim 3   , wherein said substituted cyclic moiety L 1  is phenyl, pyridinyl or pyrimidinyl.  
     
     
         14 . A compound of    claim 6   , wherein said substituted cyclic moiety L 1  is phenyl, pyridinyl or pyrimidinyl.  
     
     
         15 . A compound of    claim 8   , wherein said substituted cyclic moiety L 1  is phenyl, pyridinyl or pyrimidinyl.  
     
     
         16 . A compound of    claim 9   , wherein said substituted cyclic moiety L 1  is phenyl, pyridinyl or pyrimidinyl.  
     
     
         17 . A compound of    claim 10   , wherein said substituted cyclic moiety L 1  is phenyl, pyridinyl or pyrimidinyl.  
     
     
         18 . A compound of    claim 14   , wherein M is one or more bridging groups selected from the group consisting of —O—, —S—, —N(R 7 )—, —(CH 2 ) m —, —C(O)—, —CH(OH)—, —(CH 2 ) m O—, —(CH 2 ),S—, —(CH 2 ) m N(R 7 )—, —O(CH 2 ) m — CHX a —, —CX a   2 —, —S—(CH 2 ) m — and —N(R 7 )(CH 2 ) m —, where m=1-3, X a  is halogen and R 7  is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen up to per halo.  
     
     
         19 . A compound of    claim 15   , wherein M is one or more bridging groups selected from the group consisting of —O—, —S—, —N(R 7 )—, —(CH 2 )m—, —C(O)—, —CH(OH)—, —(CH 2 ) m O—, —(CH 2 ) m S—, —(CH 2 ) m N(R 7 )—, —O(CH 2 ) m — CHX a —, —CX a   2 —, —S—(CH 2 ) m — and —N(R 7 )(CH 2 ) m —, where m=1-3, X a  is halogen and R 7  is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen up to per halo.  
     
     
         20 . A compound of    claim 16   , wherein M is one or more bridging groups selected from the group consisting of —O—, —S—, —N(R 7 )—, —(CH 2 ) m —, —C(O)—, —CH(OH)—, —(CH 2 ) m O—, —(CH 2 ) m S—, —(CH 2 ) m N(R 7 )—, —O(CH 2 ) m — CHX a —, —CX a   2 —, —S—(CH 2 ) m — and —N(R 7 )(CH 2 ) m —, where m=1-3, X a  is halogen and R 7  is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen up to per halo.  
     
     
         21 . A compound of    claim 17   , wherein M is one or more bridging groups selected from the group consisting of —O—, —S—, —N(R 7 )—, —(CH 2 )m—, —C(O)—, —CH(OH)—, —(CH 2 ) m O—, —(CH 2 ) m S—, —(CH 2 ) m N(R 7 )—, —O(CH 2 ) m — CHX a —, —CX a   2 —, —S—(CH 2 ) m — and —N(R 7 )(CH 2 ) m —, where m-=1-3, X a  is halogen and R 7  is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen up to per halo.  
     
     
         22 . A compound of    claim 1    wherein L 1  is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C 1 -C 10  alkyl, up to per halo substituted C 1 -C 10  alkyl, —CN, —OH, halogen, C 1 -C 10  alkoxy and up to per halo substituted C 1 -C 10  alkoxy.  
     
     
         23 . A compound of    claim 13    wherein L 1  is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C 1 -C 10  alkyl, up to per halo substituted C 1 -C 10  alkyl, —CN, —OH, halogen, C 1 -C 10  alkoxy and up to per halo substituted C 1 -C 10  alkoxy.  
     
     
         24 . A compound of    claim 18    wherein L 1  is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C 1 -C 10  alkyl, up to per halo substituted C 1 -C 10  alkyl, —CN, —OH, halogen, C 1 -C 10  alkoxy and up to per halo substituted C 1 -C 10  alkoxy.  
     
     
         25 . A compound of    claim 19    wherein L 1  is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C 1 -C 10  alkyl, up to per halo substituted C 1 -C 10  alkyl, —CN, —OH, halogen, C 1 -C 10  alkoxy and up to per halo substituted C 1 -C 10  alkoxy.  
     
     
         26 . A compound of    claim 20    wherein L 1  is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C 1 -C 10  alkyl, up to per halo substituted C 1 -C 10  alkyl, —CN, —OH, halogen, C 1 -C 10  alkoxy and up to per halo substituted C 1 -C 10  alkoxy.  
     
     
         27 . A compound of    claim 21    wherein L 1  is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C 1 -C 10  alkyl, up to per halo substituted C 1 -C 10  alkyl, —CN, —OH, halogen, C 1 -C 10  alkoxy and up to per halo substituted C 1 -C 10  alkoxy.  
     
     
         28 . A compound of    claim 1    wherein L 1  is substituted by —C(O)R x .  
     
     
         29 . A compound of    claim 1    wherein L 1  is substituted by —SO 2 R x .  
     
     
         30 . A compound of    claim 1    wherein L 1  is substituted only by —C(O)R x .  
     
     
         31 . A compound of    claim 1    wherein L 1  is substituted only by —SO 2 R x .  
     
     
         32 . A compound of    claim 1    wherein L 1  is substituted by —C(O)R x  or —SO 2 R x , wherein R x  is NR a R b .  
     
     
         33 . A compound of    claim 13    wherein L 1  is substituted by —C(O)R x  or —SO 2 R x , wherein R x  is NR a R b , and R a  and R b  are 
 a) independently hydrogen,  
 a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and a re optionally substituted by halogen, or  
 —OSi(R f ) 3  where R f  is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or  
 b) R a  and R b  together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or  
 c) one of R a  or R b  is —C(O)—, a C 1 -C 5  divalent alkylene group or a substituted C 1 -C 5  divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C 1 -C 5  divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.  
 
     
     
         34 . A compound of    claim 18    wherein L 1  is substituted by —C(O)R x  or —SO 2 R x , wherein R x  is NR a R b  and R a  and R b  are independently hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.  
     
     
         35 . A compound of    claim 19    wherein L 1  is substituted by —C(O)R x , wherein R x  is NR a R b  and R a  and R b  are independently hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.  
     
     
         36 . A compound of    claim 20    wherein L 1  is substituted by —C(O)R x  or —SO 2 R x , wherein R x  is NR a R b  and R a  and R b  are independently hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.  
     
     
         37 . A compound of    claim 21    wherein L 1  is substituted by —C(O)R x  or —SO 2 R x , wherein R x  is NR a R b  and R a  and R b  are independently hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.  
     
     
         38 . A compoundof Formula I: 
       A−D−B   (I) 
       or a pharmaceutically acceptable salt thereof, wherein 
 D is —NH—C(O)—NH—,  
 A is a substituted moiety of up to 40 carbon atoms of the formula: —L—(M—L 1 ) q , where L is a 6 membered aryl moiety or a 6 membered hetaryl moiety bound directly to D, L 1  comprises a substituted cyclic moiety having at least 5 members, M is a bridging group having at least one atom, q is an integer of from 1-3; and each cyclic structure of L and L 1  contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur, and  
 B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur,  
 wherein L 1  is substituted by at least one substituent selected from the group consisting of —SO 2 R x , —C(O)R x  and —C(NR y ) R z ,  
 R y  is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo,  
 R z  is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;  
 R x  is R z  or NR a R b  where R a  and R b  are 
 a) independently hydrogen,  
 
 a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or  
 —OSi(R f ) 3  where R f  is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or 
 b) R a  and R b  together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or  
 c) one of R a  or R b  is —C(O)—, a C 1 -C 5  divalent alkylene group or a substituted C 1 -C 5  divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C 1 -C 5  divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;  
 
 where B is substituted, L is substituted or L 1  is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and Wn, where n is 0-3;  
 wherein each W is independently selected from the group consisting of —CN, —CO 2 R 7 , —C(O)NR 7 R 7 , —C(O)—R 7 , —NO 2 , —OR 7 , —SR 7 , —NR 7 R 7 , —NR 7 C(O)OR 7 , —NR 7 C(O)R 7 , —Q—Ar, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of —CN, —CO 2 R 7 , —C(O)R 7 , —C(O)NR7 R7, —OR7, —SR7, —NR 7 R 7 , —NO 2 , —NR 7 C(O)R 7 , —NR 7 C(O)OR 7  and halogen up to per-halo; with each R 7  independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen,  
 wherein Q is —O—, —S—, —N(R 7 )—, —(CH 2 ) m —, —C(O)—, —CH(OH)—, —(CH 2 ) m O—, —(CH 2 ) m S—, —(CH 2 ) m N(R 7 )—, —O(CH 2 ) m — CHX a —, —CX a   2 —, —S—(CH 2 ) m — and —N(R 7 )(CH 2 ) m —, where m=1-3, and X a  is halogen;  
 Ar is a 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by Z n1  wherein nl is O to 3 and each Z is independently selected from the group consisting of —CN, —CO 2 R 7 , —C(O)R 7 , —C(O)NR 7 R 7 , —NO 2 , —OR 7 , —SR 7  —NR 7 R 7 , —NR 7 C(O)OR 7 , —NR 7 C(O)R 7 , and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents are selected from the group consisting of —CN, —CO 2 R 7 , —COR 7 , —C(O)NR 7 R 7 , —OR 7 , —SR 7 , —NO 2 , —NR 7 R 7 , —NR 7 C(O)R 7 , and —NR 7 C(O)OR 7 , with R 7  as defined above; and  
 wherein M is one or more bridging groups selected from the group consisting of —O—, —S—, —N(R 7 )—, —(CH 2 ) m —, —C(O)—, —CH(OH)—, —(CH 2 ) m O—, —(CH 2 ) m S—, —(CH 2 ) m N(R 7 )—, —O(CH 2 ) m — CHX a —, —CX a   2 —, —S—(CH 2 ) m — and —N(R 7 )(CH 2 ) m —, where m=1—3, X a  is halogen.  
 
     
     
         39 . A compound of Formula I: 
       A−D−B   (I) 
       or a pharmaceutically acceptable salt thereof, wherein 
 D is —NH—C(O)—NH—,  
 A is a substituted moiety of up to 40 carbon atoms of the formula: —L—(M—L 1 ) q , where L is a substituted or unsubstituted phenyl or peritoneal moiety bound directly to D, L 1  comprises a substituted phenyl, peritoneal or pyrimidinyl moiety, M is a bridging group having at least one atom, q is an integer of from 1-3; and  
 B is a substituted or unsubstituted phenyl or pyridine group bound directly to D,  
 wherein L 1  is substituted by at least one substituent selected from the group consisting of —SO 2 R x , —C(O)R, and —C(NR y ) R z ,  
 R y  is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo, and;  
 R z  is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;  
 R x  is R z  or NR a R b  where R a  and R b  are  
 a) independently hydrogen, 
 a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or  
 —OSi(R f ) 3  where R f  is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or  
 
 b) R a  and R b  together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or  
 c) one of R a  or R b  is —C(O)—, a C 1 -C 5  divalent alkylene group or a substituted C 1 -C 5  divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C 1 -C 5  divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;  
 where B is substituted, L is substituted or L 1  is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and Wn, where n is 0-3;  
 wherein each W is independently selected from the group consisting of —CN, —CO 2 R 7 , —C(O)NR 7 R 7 , —C(O)—R 7 , —NO 2 , —OR 7 , —SR 7 , —NR 7 R 7 , —NR 7 C(O)OR 7 , —NR 7 C(O)R 7 , —Q—Ar, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of —CN, —CO 2 R 7 , —C(O)R 7 , —C(O)NR 7 R 7 , —OR, —SR, —NR 7 R 7 , —NO 2 , —NR 7 C(O)R 7 , —NR 7 C(O)OR 7  and halogen up to per-halo; with each R 7  independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen,  
 wherein Q is —O—, —S—, —N(R 7 )—, —(CH 2 ) m —, —C(O)—, —CH(OH)—, —(CH 2 ) m O—, —(CH 2 ) m S—, —(CH 2 ) m N(R 7 )—, —O(CH 2 ) m — CHX a —, —CX a   2 —, —S—(CH 2 ) m — and —N(R 7 )(CH 2 ) m —, where m=1-3, and X a  is halogen;  
 Ar is a 5- or 6- member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by Z n1 , wherein n1 is O to 3 and each Z is independently selected from the group consisting of —CN, —CO 2 R 7 , —C(O)R 7 , —C(O)NR 7 R 7 , —NO 2 , —OR 7 , —SR 7  —NR 7 R 7 , —NR 7 C(O)OR 7 , —NR 7 C(O)R 7 , and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents selected from the group consisting of —CN, —CO 2 R 7 , —COR 7 , —C(O)NR 7 R 7 , —OR 7 , —SR 7 , —NO 2 , —NR 7 R 7 , —NR 7 C(O)R 7 , and —NR 7 C(O)OR 7 ; and wherein M is one or more bridging groups selected from the group consisting of —O—, —S—, —N(R 7 )—, —(CH 2 ) m —, —C(O)—, —CH(OH)—, —(CH 2 ) m O—, —(CH 2 ) m S—, —(CH 2 ) m N(R 7 )—, —O(CH 2 ) m —CHX a —, —CX a   2 —, —S—(CH 2 ) m — and —N(R 7 )(CH 2 ) m —, where m=1—3, X a  is halogen.  
 
     
     
         40 . A compound as in    claim 38    wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by —OH.  
     
     
         41 . A compound as in    claim 38    wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by a moiety having an ionizable hydrogen and a pKa of 10 or less.  
     
     
         42 . A compound as in    claim 39    wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by —OH.  
     
     
         43 . A compound as in    claim 39    wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by a moiety having an ionizable hydrogen and a pKa of 10 or less.  
     
     
         44 . A compound as in    claim 38    wherein substituents for B and L and additional substituents for L 1 , are selected from the group consisting of C 1 -C 10  alkyl up to per halo substituted C 1 -C 10  alkyl, CN, OH, halogen, C 1 -C 10  alkoxy and up to per halo substituted C 1 -C 10  alkoxy.  
     
     
         45 . A compound as in    claim 39    wherein substituents for B and L and additional substituents for L 1 , are selected from the group consisting of C 1 -C 10  alkyl up to per halo substituted C 1 -C 10  alkyl, CN, OH, halogen, C 1 -C 10  alkoxy and up to per halo substituted C 1 -C 10  alkoxy.  
     
     
         46 . A compound of    claim 38    wherein L 1  is substituted by C(O)R X  or SO 2 R x .  
     
     
         47 . A compound of    claim 39    wherein L 1  is substituted by C(O)R X  or SO 2 R x .  
     
     
         48 . A compound of    claim 46    wherein R x  is NR a R b  and R a  and R b  are independently hydrogen and a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen..  
     
     
         49 . A compound of    claim 47    wherein R x  is NR a R b  and R a  and R b  are independently hydrogen and a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.  
     
     
         50 . A compound of    claim 1    which is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of 
 a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and  
 b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.  
 
     
     
         51 . A compound of    claim 2    which is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of 
 a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and  
 b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.  
 
     
     
         52 . A compound of    claim 33    which is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of 
 a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and  
 b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.  
 
     
     
         53 . A compound of    claim 38    which is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of 
 a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and  
 b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.  
 
     
     
         54 . A compound of    claim 39    which is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of 
 a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and  
 b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.  
 
     
     
         55 . A pharmaceutical composition comprising a compound of    claim 1    or a pharmaceutically acceptable salt of a compound of formula I, and a physiologically acceptable carrier.  
     
     
         56 . A pharmaceutical composition comprising a compound of    claim 2    consistent with formula I or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.  
     
     
         57 . A pharmaceutical composition comprising a compound of    claim 33    consistent with formula I or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.  
     
     
         58 . A pharmaceutical composition comprising a compound of    claim 38    consistent with formula I or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.  
     
     
         59 . A pharmaceutical composition comprising a compound of    claim 39    consistent with formula I or a pharmaceutically acceptable salt thereof and a physiologically acceptable carrier.  
     
     
         60 . A compound selected from the group consisting of 3-lert butyl phenyl ureas of Table 1 above; 
 5-tert butyl-2-methoxyphenyl ureas of Table 2 above;    5-(trifluoromethyl)-2 phenyl ureas of Table 3 above;    3-(trifluoromethyl) -4 chlorophenyl ureas of Table 4 above;    3-(trifluoromethyl)-4-bromophenyl ureas of Table 5 above;    5-(trifluoromethyl)-4-chloro-2 methoxyphenyl ureas of Table 6 above; and    ureas 101-103 in Table 7 above.    
     
     
         61 . A compound selected from the group consisting of the 3-tert butyl phenyl ureas: 
 N-(3-tert-butylphenyl)-N′-(4-(3-(N-methylcarbamoyl)phenoxy)phenyl urea and N-(3-tert-butylphenyl)-N′-(4-(4-acetylphenoxy)phenyl urea;    the 5-tert-butyl-2-methoxyphenyl ureas:    N-(5-tert-butyl-2-methoxyphenyl)-N′-(4-(1,3-dioxoisoindolin-5-yloxy)phenyl) urea,    N-(5-tert-butyl-2-methoxyphenyl)-N′-(4-(1-oxoisoindolin-5-yloxy)phenyl) urea,    N-(5-tert-butyl-2-methoxyphenyl)-N′-(4-(4-methoxy-3-(N-methylcarbamoyl)phenoxy)phenyl) urea and    N-(5-tert-butyl-2-methoxyphenyl)-N′-(4-(3-(N-methylcarbamoyl)phenoxy)phenyl) urea;    the 2-methoxy-5-trifluoromethyl)phenyl ureas:    N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,    N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(3-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,    N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,    N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridylthio)phenyl) urea,    N-(2-methoxy-5 -(trifluoromethyl)phenyl)-N′-(2-chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and    N-(2-methoxy-5 -(trifluoromethyl)phenyl)-N′-(3 -chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea;    the 4-chloro-3-(trifluoromethyl)phenyl ureas:    N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,    N-(4-chloro-3 -(trifluoromethyl)phenyl)-N′-(3-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,    N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea and N-(4-chloro-3 -(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.    the 4-romo-3-(trifluoromethyl)phenyl ureas:    N-(4-bromo-3 -(trifluoromethyl)phenyl)-N′-(3 -(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,    N-(4-bromo-3 -(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,    N-(4-bromo-3-(trifluoromethyl)phenyl)-N′-(3-(2-(N-methylcarbamoyl)-4-pyridylthio)phenyl) urea,    N-(4-bromo-3-(trifluoromethyl)phenyl)-N′-(2-chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and    N-(4-bromo-3-(trifluoromethyl)phenyl)-N ′-(3 -chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea; and    the 2-methoxy-4-chloro-5-(trifluoromethyl)phenyl ureas:    N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N′-(3-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,    N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,    N-(2-methoxy-4-chloro-5 -(trifluoromethyl)phenyl)-N′-(2-chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and    N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N′-(3 -chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea.    
     
     
         62 . A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of Formula I of    claim 1   .  
     
     
         63 . A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of Formula I of    claim 33   .  
     
     
         64 . A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of Formula I of    claim 38   .  
     
     
         65 . A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of Formula I of    claim 39   .  
     
     
         66 . A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administrating a compound selected from the group consisting of 
 3-tert butyl phenyl ureas of Table 1 above;    5-tert butyl-2-methoxyphenyl ureas of Table 2 above;    5-(trifluoromethyl)-2 phenyl ureas of Table 3 above;    3-(trifluoromethyl) 4 chlorophenyl ureas of Table 4 above;    3-(trifluoromethyl)-4-bromophenyl ureas of Table 5 above;    5-(trifluoromethyl)-4-chloro-2 methoxyphenyl ureas of Table 6 above; and ureas 101-103 in Table 7 above.    
     
     
         67 . A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administrating a compound selected from the group consisting of the 3-tert butyl phenyl ureas: 
 N-(3-tert-butylphenyl)-N′-(4-(3-(N-methylcarbamoyl)phenoxy)phenyl urea and N-(3-tert-butylphenyl)-N′-(4-(4-acetylphenoxy)phenyl urea;    the 5-tert-butyl-2-methoxyphenyl ureas:    N-(5-tert-butyl-2-methoxyphenyl)-N′-(4-(1,3-dioxoisoindolin-5-yloxy)phenyl) urea,    N-(5-tert-butyl-2-methoxyphenyl)-N′-(4-(1-oxoisoindolin-5-yloxy)phenyl) urea,    N-(5-tert-butyl-2-methoxyphenyl)-N′-(4-(4-methoxy-3 -(N-methylcarbamoyl)phenoxy)phenyl) urea and    N-(5-tert-butyl-2-methoxyphenyl)-N′-(4-(3-(N-methylcarbamoyl)phenoxy)phenyl) urea;    the 2-methoxy-5-trifluoromethyl)phenyl ureas:    N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,    N-(2-methoxy-5-(trifluoromethyl)phenyl) -N ′-(3 -(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,    N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,    N-(2-methoxy-5 -(trifluoromethyl)phenyl)-N ′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,    N-(2-methoxy-5-(trifluoromethyl)phenyl)-N ′-(4-(2-(N-methylcarbamoyl)-4-pyridylthio)phenyl) urea,    N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(2-chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and    N-(2-methoxy-5-(trifluoromethyl)phenyl)-N ′-(3 -chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea;    the 4-chloro-3-(trifluoromethyl)phenyl ureas:    N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,    N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(3-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,    N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea and    N-(4-chloro-3 -(trifluoromethyl)phenyl)-N ′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea;    the 4-romo-3-(trifluoromethyl)phenyl ureas:    N-(4-bromo-3-(trifluoromethyl)phenyl)-N′-(3-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,    N-(4-bromo-3 -(trifluoromethyl)phenyl)-N ′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,    N-(4-bromo-3-(trifluoromethyl)phenyl)-N′-(3 -(2-(N-methylcarbamoyl)-4-pyridylthio)phenyl) urea,    N-(4-bromo-3-(trifluoromethyl)phenyl)-N ′-(2-chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and    N-(4-bromo-3-(trifluoromethyl)phenyl)-N ′-(3 -chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea; and    the 2-methoxy-4-chloro-5-(trifluoromethyl)phenyl ureas:    N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N′-(3 -(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,    N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,    N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N′-(2-chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and    N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N′-(3 -chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea.